Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 12/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991401 | 1.00 | PIK3CD (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGERBB2 | |
| SCHEMBL5458764 | 0.92 | ERBB2 (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGERBB2 | |
| SCHEMBL5466136 | 0.92 | ERBB2 (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGERBB2 | |
| SCHEMBL2453138 | 0.83 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGERBB2 | |
| SCHEMBL665187 | 0.83 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGERBB2 | |
| SCHEMBL29465791 | 0.83 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGERBB2 | |
| SCHEMBL29465790 | 0.83 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGERBB2 | |
| SCHEMBL1989563 | 0.83 | EGFR (0.64) | ERBB2EPHA2EPHB4EGFR | |
| SCHEMBL1986916 | 0.83 | EGFR (0.64) | ERBB2EPHA2EPHB4EGFR | |
| SCHEMBL29834734 | 0.82 | PIK3CD (0.62) | PIK3CDPIK3CAPIK3CBPIK3CGERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856095-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-24 | — | — | EP | disclosed |
| US-20110152297-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Astra Zeneca AB Corporation | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152297-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | PIK3CD 264/4885PIK3CA 216/4885PIK3CB 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.